STOCK TITAN

AI/ML Innovations Inc. Provides Status Update

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags
AI

AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB) has provided a status update regarding its management cease trade order (MCTO) granted by the British Columbia Securities Commission on August 29, 2024. The MCTO restricts trading for the CEO and Interim CFO until the company files its annual financial documents for the year ended April 30, 2024. The company now expects to file these documents by September 30, 2024, citing ongoing work with auditors on accounting issues related to a French investee entity.

AI/ML Innovations is focused on artificial intelligence and machine learning in digital health and wellbeing. The company has investments in Health Gauge (70% owned), Tech2Heal (22% ownership commitment), and AI Rx Inc. (70% owned), aiming to capitalize on growth areas in healthcare management solutions and precision support delivery.

AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB) ha fornito un aggiornamento sullo stato del suo ordine di cessazione delle negoziazioni per la gestione (MCTO) concesso dalla British Columbia Securities Commission il 29 agosto 2024. Il MCTO limita le negoziazioni per il CEO e il CFO ad interim fino a quando la società non presenta i documenti finanziari annuali per l'anno concluso il 30 aprile 2024. La società ora prevede di presentare tali documenti entro il 30 settembre 2024, citando il lavoro in corso con i revisori sui problemi contabili relativi a un'entità investita francese.

AI/ML Innovations è focalizzata su intelligenza artificiale e machine learning nella salute digitale e nel benessere. L'azienda ha investimenti in Health Gauge (70% di proprietà), Tech2Heal (impegno di proprietà del 22%) e AI Rx Inc. (70% di proprietà), con l'obiettivo di capitalizzare le aree di crescita nelle soluzioni di gestione sanitaria e nella consegna di supporto di precisione.

AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB) ha ofrecido una actualización sobre el estado de su orden de cese de comercio para la gestión (MCTO) concedido por la Comisión de Valores de Columbia Británica el 29 de agosto de 2024. El MCTO restringe el comercio para el CEO y el CFO interino hasta que la empresa presente sus documentos financieros anuales para el año terminado el 30 de abril de 2024. La empresa ahora espera presentar estos documentos para el 30 de septiembre de 2024, citando trabajos en curso con auditores sobre problemas contables relacionados con una entidad francesa en la que ha invertido.

AI/ML Innovations se centra en inteligencia artificial y aprendizaje automático en salud digital y bienestar. La empresa posee inversiones en Health Gauge (70% de propiedad), Tech2Heal (compromiso de propiedad del 22%) y AI Rx Inc. (70% de propiedad), con el objetivo de capitalizar áreas de crecimiento en soluciones de gestión sanitaria y entrega de soporte de precisión.

AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB)는 2024년 8월 29일 브리티시컬럼비아 증권위원회에서 부여한 관리 거래 중지 명령(MCTO)에 대한 상태 업데이트를 제공했습니다. MCTO는 CEO와 임시 CFO의 거래를 2024년 4월 30일 종료된 연도의 연간 재무 문서가 제출될 때까지 제한합니다. 회사는 이제 2024년 9월 30일까지 이러한 문서를 제출할 것으로 예상하고 있습니다, 프랑스 출자 회사와 관련된 회계 문제에 대해 감사인과의 진행 중인 작업을 언급했습니다.

AI/ML Innovations는 디지털 건강 및 웰빙 분야의 인공 지능 및 기계 학습에 집중하고 있습니다. 이 회사는 Health Gauge (70% 소유), Tech2Heal (22% 소유 약속), AI Rx Inc. (70% 소유)에 투자하고 있으며, 의료 관리 솔루션 및 정밀 지원 제공의 성장 분야에서 혜택을 보고자 합니다.

AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB) a fourni une mise à jour concernant son ordre de cessation de négociation pour la direction (MCTO) accordé par la Commission des valeurs mobilières de la Colombie-Britannique le 29 août 2024. Le MCTO limite les opérations pour le PDG et le directeur financier intérimaire jusqu'à ce que la société dépose ses documents financiers annuels pour l'exercice clos le 30 avril 2024. La société s'attend désormais à déposer ces documents d'ici le 30 septembre 2024, citant le travail en cours avec les auditeurs sur des problèmes de comptabilité liés à une entité investie française.

AI/ML Innovations se concentre sur l'intelligence artificielle et l'apprentissage automatique dans la santé numérique et le bien-être. L'entreprise a des investissements dans Health Gauge (70% de propriété), Tech2Heal (engagement de propriété de 22%) et AI Rx Inc. (70% de propriété), visant à tirer parti des domaines de croissance dans les solutions de gestion de la santé et la livraison de soutien de précision.

AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB) hat ein Statusupdate zu seiner Management-Handelsstoppverordnung (MCTO) gegeben, die am 29. August 2024 von der British Columbia Securities Commission gewährt wurde. Die MCTO beschränkt den Handel für den CEO und den Interim CFO, bis das Unternehmen seine jährlichen Finanzunterlagen für das am 30. April 2024 endende Jahr einreicht. Das Unternehmen erwartet jetzt, diese Unterlagen bis zum 30. September 2024 einzureichen und verweist auf die laufende Zusammenarbeit mit Wirtschaftsprüfern zu buchhalterischen Fragen im Zusammenhang mit einem französischen Beteiligungsunternehmen.

AI/ML Innovations konzentriert sich auf künstliche Intelligenz und maschinelles Lernen im Bereich digitale Gesundheit und Wohlbefinden. Das Unternehmen hat Investitionen in Health Gauge (70% Eigentum), Tech2Heal (22% Eigentumsverpflichtung) und AI Rx Inc. (70% Eigentum) und hat das Ziel, von Wachstumsbereichen in Lösungen für Gesundheitsmanagement und präziser Unterstützung zu profitieren.

Positive
  • Company is working expeditiously to file the Required Documents by September 30, 2024
  • MCTO does not affect the ability of other shareholders to trade their securities
  • Company has strategic investments in AI and ML-focused digital health companies
Negative
  • Management cease trade order (MCTO) issued due to delay in filing annual financial documents
  • Ongoing accounting issues with consolidation of a France-based investee entity
  • Risk of issuer cease trade order if Required Documents are not filed in a timely manner

VICTORIA, BC / ACCESSWIRE / September 6, 2024 / AI/ML Innovations Inc. (the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB) announces that further to its news releases dated August 23, 2024 and August 29, 2024, the Company's principal regulator, the British Columbia Securities Commission (the "BCSC"), granted a management cease trade order (the "MCTO") on August 29, 2024 under National Policy 12-203 Management Cease Trade Orders ("NP 12-203"). Pursuant to the MCTO, Paul Duffy, the Chief Executive Officer, and Tim Daniels, the Interim Chief Financial Officer, may not trade in securities of the Company until such time as the Company files its annual audited financial statements, annual management's discussion and analysis and related certifications for the year ended April 30, 2024 (collectively, the "Required Documents"), and the Executive Director of the BCSC revokes the MCTO. The MCTO does not affect the ability of other shareholders to trade their securities.

The Company's Board of Directors and management confirm that they are working expeditiously to file the Required Documents and now expect to do so on or before September 30, 2024, and confirm that since the Company's news release dated August 29, 2024, there is no other material information respecting the Company's affairs that has not been generally disclosed. The Company continues to work with its auditor in relation to accounting issues raised regarding the consolidation of a France based investee entity.

Until the Required Documents have been filed, the Company intends to continue to satisfy the provisions of the alternative information guidelines specified in NP 12-203 by issuing bi-weekly default status reports in the form of further press releases for so long as the Company remains in default of the financial statement filing requirement. In the event that the Company does not file the Required Documents in a timely manner, the Canadian Securities Regulatory Authorities may impose an issuer cease trade order on the outstanding securities of the Company.

For more information about AI/ML Innovations:

For detailed information please see AI/ML's website or the Company's filed documents at www.sedarplus.ca.

For further information, contact: Blake Fallis at (778) 405-0882 or info@aiml-innovations.com.

About AI/ML Innovations Inc.https://aiml-innovations.com/

AI/ML Innovations Inc. has realigned its business operations to capitalize on the burgeoning fields of artificial intelligence (AI) and machine learning (ML), with an initial investment focus on emerging digital health and wellbeing companies that leverage AI, ML, cloud computing and digital platforms to drive transformative healthcare management solutions and precision support delivery across the health continuum. Through strategic partnerships with Health Gauge (70% owned by AIML), Tech2Heal (22% ownership commitment by AIML), AI Rx Inc. (70% owned by AIML) and other planned accretive investments, the Company continues to capitalize on expanding growth areas, to the benefit of all the Company's stakeholders. AI/ML's shares are traded on the Canadian Securities Exchange under the symbol "AIML", the OTCQB Venture Market under "AIMLF", and the Frankfurt Stock Exchange under "42FB".

Certain statements in this news release are "forward-looking statements", which reflect management's expectations regarding the timing of filing of the Required Documents. All statements other than statements of historical fact contained in this news release are forward-looking statements. Such forward-looking statements involve risks and uncertainties, as they reflect management's current beliefs and are based on information currently available to management. Actual results may differ materially from those anticipated in the statements made. The forward-looking statements are expressly qualified in their entirety by this cautionary statement. The forward-looking statements are made as of the date of this news release and the Company assumes no obligation to update or revise them to reflect new events or circumstances except as expressly required by applicable securities law. Further information regarding the uncertainties and risks can be found in the disclosure documents filed by the Company with the securities regulatory authorities, available at www.sedarplus.ca.

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: AI/ML Innovations, Inc.



View the original press release on accesswire.com

FAQ

What is the current status of AI/ML Innovations Inc.'s (AIMLF) management cease trade order?

AI/ML Innovations Inc. (AIMLF) is under a management cease trade order (MCTO) issued by the British Columbia Securities Commission on August 29, 2024. The MCTO restricts trading for the CEO and Interim CFO until the company files its annual financial documents for the year ended April 30, 2024.

When does AI/ML Innovations Inc. (AIMLF) expect to file its required financial documents?

AI/ML Innovations Inc. (AIMLF) expects to file its required financial documents, including annual audited financial statements, management's discussion and analysis, and related certifications for the year ended April 30, 2024, by September 30, 2024.

What are the main business focus areas of AI/ML Innovations Inc. (AIMLF)?

AI/ML Innovations Inc. (AIMLF) focuses on artificial intelligence (AI) and machine learning (ML) in digital health and wellbeing. The company has strategic investments in Health Gauge, Tech2Heal, and AI Rx Inc., targeting healthcare management solutions and precision support delivery across the health continuum.

AI / ML INNOVATIONS INC

OTC:AIMLF

AIMLF Rankings

AIMLF Latest News

AIMLF Stock Data

5.74M
50.38M
10.47%
Health Information Services
Healthcare
Link
United States of America
Victoria